Okoumé Capital S.A. announced that it has obtained approval from the Central African Financial Market Supervisory Commission (COSUMAF) as a Management Company for Private Equity Funds. According to a statement from the company, this authorization was granted under reference COSUMAF-SGO-01/2026 dated March 10, 2026. The company also specifies that its managing director, Fabrice Ulric Assoumou Essono, and its deputy managing director, Nadia Prisca Ngoyo Moussavou, have been approved as leaders of the structure.
For Okoumé Capital, this regulatory decision marks a significant milestone in its development. The company sees it as recognition of the structuring work undertaken, a strengthening of its institutional credibility, and a consolidation of its position as a trusted player in private equity, poised to contribute sustainably to the financing of the real economy in Central Africa. In the statement, the chairman of the board of directors, Stéphane Mbadinga Ditengou, highlights the robustness of the framework, the rigor of governance, and the commitment to channel long-term savings into useful, productive, and value-creating investments.
Through this approval, the company asserts its ambition to mobilize long-term resources for growth-oriented, transformative, and impactful companies. It aligns this dynamic with regional economic priorities, including productive investment, support for employment, economic diversification, and the promotion of good environmental, social, and governance practices. Okoumé Capital also indicates its intention to continue strengthening its internal standards and structuring its interventions to contribute to the development of a credible, demanding, and sustainable private equity sector in the region.
Beyond the institutional announcement, this approval provides Okoumé Capital with a clearer regulatory and governance framework to deploy its activities. In a sector where investor confidence largely relies on supervision, management discipline, and the quality of leadership, this validation by COSUMAF can be seen as a lever for credibility. It also aligns the company with a growing demand for patient capital directed towards companies capable of supporting the productive transformation of Central Africa.